Pharminent

Mundipharma to launch Mabthera biosimilar in EU markets

Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory conditions, after Celltrion bagged a regulatory approval for the drug. http://www.pharmatimes.com/news/mundipharma_to_launch_mabthera_biosimilar_in_eu_markets_1187412

Filed under: Biosimilar